HR
SRPT icon

Howe & Rusling’s Sarepta Therapeutics SRPT Stock Holding History

Howe & Rusling’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-149
Closed -$11K – 1184
2022
Q2 		$11K Buy
+149
New +$11K ﹤0.01% 527
2020
Q1 		– Sell
-10
Closed -$1K – 870
2019
Q4 		$1K Hold
10
– – ﹤0.01% 788
2019
Q3 		$1K Sell
10
-7
-41% -$827 ﹤0.01% 796
2019
Q2 		$3K Hold
17
– – ﹤0.01% 625
2019
Q1 		$2K Sell
17
-20
-54% -$2.57K ﹤0.01% 686
2018
Q4 		$4K Hold
37
– – ﹤0.01% 579
2018
Q3 		$6K Hold
37
– – ﹤0.01% 586
2018
Q2 		$5K Hold
37
– – ﹤0.01% 560
2018
Q1 		$3K Buy
37
+17
+85% +$1.13K ﹤0.01% 720
2017
Q4 		$1K Buy
+20
New +$1.06K ﹤0.01% 802

Other funds holding SRPT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Howe & Rusling's SRPT Position: Q3 2022 in Review

Howe & Rusling sold out of Sarepta Therapeutics (SRPT) in Q3 2022, closing a stake of 149 shares — an estimated $11K sold.

Howe & Rusling first reported a position in SRPT in Q4 2017 and held it in 10 quarters. The position peaked at $11K in Q2 2022. 375 funds tracked by Wall St. Rank hold SRPT as of Q3 2022.

  • Howe & Rusling reported no remaining Sarepta Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Howe & Rusling sold 149 Sarepta Therapeutics shares in Q3 2022, an estimated $11K.
  • Howe & Rusling first reported a position in Sarepta Therapeutics in Q4 2017 and held it in 10 quarters.
  • Howe & Rusling's Sarepta Therapeutics position peaked at $11K in Q2 2022.
  • 375 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2022.

Based on Howe & Rusling's 13F filing for Q3 2022, filed 14 Nov 2022.